Articles related to LEUKEMIA

Discover why CPX-351 extends relapse-free survival but does not significantly alter overall survival in younger AML/MDS patients, as revealed by the UK NCRI AML19 trial.

The recent study on vemurafenib and obinutuzumab offers a promising treatment pathway for previously untreated HCL patients, achieving high rates of complete remission and minimal residual disease negativity.

Discover how base editing via CRISPR-guided cytidine deamination could revolutionize CAR T-cell therapy for T-cell cancers, offering a promising approach to treating relapsed or refractory cases in pediatric patients.

Explore the findings of the A041702 study, presented at the ASCO annual meeting, which investigated the efficacy of two treatment regimens for older patients with CLL. The results, significantly influenced by COVID-19, call for further investigation and long-term follow-up to determine the potential benefits and risks.

This is a golden opportunity to bolster your understanding of AML, implement novel diagnostic strategies, and integrate state-of-the-art treatment plans into your practice. Enrich your professional knowledge, earn valuable CME credits, and most importantly, help improve the lives of your patients.

Uncover the potential of nivolumab and axicabtagene ciloleucel as they showcase promising results in the latest lymphoma trials, potentially reshaping the standard of care for these malignancies.